Solid tumors represent the majority of cancer diagnoses globally. While they may differ in location—ranging from breast and lung to gastrointestinal and reproductive systems—what unites them is the increasing importance of understanding their underlying genetic drivers. Today, treatment decisions are no longer made by tumor type alone, but by the specific molecular alterations that shape disease behavior.
At Genomenon, we believe the foundation of precision oncology is precise data. That’s why the Cancer Knowledgebase (CKB) offers expertly curated, biomarker-specific content designed to support clinical decision-making, research, and therapeutic development for solid tumors.
Why Genomics is Transforming Solid Tumor Oncology
The discovery of actionable variants—such as those found in EGFR, BRCA1/2, KRAS, BRAF, and PIK3CA—has dramatically shifted how solid tumors are diagnosed, treated, and monitored. These biomarkers inform targeted therapy selection, guide resistance monitoring, and determine patient eligibility for clinical trials.
However, identifying these variants isn’t enough. Their interpretation requires curated evidence that is trustworthy, comprehensive, and clinically meaningful.
This is where CKB provides a critical advantage.
CKB’s Solid Tumor Coverage: Precision Built for Impact
CKB’s robust annotation library highlights the breadth of genomic research across major solid tumor types.
- Lung cancer leads with over 7,100 efficacy annotations, reflecting its central role in precision oncology and the high volume of biomarker-driven therapies in development and use.
- Gastrointestinal cancers follow closely, with nearly 5,000 annotations covering colorectal, esophageal, and gastric tumors—tumors often driven by complex variant profiles requiring nuanced interpretation.
- Breast cancer contributes nearly 4,000 annotations, encompassing well-established markers like BRCA1/2 and emerging targets across triple-negative and hormone-sensitive subtypes.
- Reproductive cancers, such as ovarian and prostate, account for over 2,500 annotations that include both germline and somatic variants with significant therapeutic relevance.
- Skin cancers, including melanoma, round out the top five with more than 2,000 annotations tied to variants within BRAF and NRAS.
Clinical Trials with Variant Requirements
In precision oncology, clinical trial enrollment often hinges on specific variant inclusion criteria. CKB helps streamline this process by mapping thousands of ongoing trials to variant-level eligibility:
- Gastrointestinal tumors top the list, with over 900 trials indexed—many of which focus on KRAS, BRAF, and microsatellite instability.
- Lung cancer trials (665 total) frequently include EGFR, ALK, and MET biomarkers, supporting patient stratification for targeted therapies.
- Breast cancer has 562 variant-driven trials, reflecting both HER2-targeted and emerging genomic approaches.
- Reproductive organ cancers include 461 trials, covering both germline and somatic variants in conditions like ovarian and prostate cancer.
- Skin cancers show 148 trials with genomic criteria, highlighting the importance of MAPK pathway genes in clinical development.
Clinical Trials by Phase
Understanding where trials fall along the development spectrum is essential for strategic planning.
- Phase I trials (1,100+) explore safety and dosage, often for first-in-human or novel combinations, giving insight into early biomarker utility.
- Phase Ib/II (900+) and Phase II (1,300+) trials mark the transition from feasibility to efficacy, where biomarker data directly inform trial design.
- Phase III trials (300+) reflect advanced-stage evidence often supporting regulatory decisions for new drugs, making them critical for understanding standard-of-care transitions.
From Insight to Implementation
CKB stands apart through its human-driven curation process. Each annotation is reviewed by variant scientists and oncogenomics experts to ensure that it meets rigorous standards for accuracy, context, and clinical utility. This approach eliminates noise and elevates the kind of high-confidence evidence that drives real-world decision-making.
As data continue to grow exponentially, it is not the quantity of information that drives progress—it is its quality.
Accelerating the Future of Oncology
Whether you're designing an actionable gene panel, developing targeted therapies, or matching patients to trials, CKB offers the genomic clarity and depth required to drive innovation in solid tumor care.
Explore how curated variant insights can help you unlock new possibilities in precision oncology. Create a CKB Account today.
📩 Contact us to learn more.
